SU5416 is a small-molecule angiogenesis inhibitor that blocks the action of vascular endothelial growth factor receptor (VEGF-R) in endothelial cells, which is critical for new blood vessel formation.

The relationship between levels of endogenous angiogenesis inhibitors, bioavailability of antiangiogenesis agents, and clinical benefits is still far from clear. Conclusions drawn from many of ...

After decades of work, Dr. Folkman and his team are now watching as clinical trials begin with two recently discovered angiogenesis inhibitors, endostatin and angiostatin. In this interview ...

Figure 2: Maspin inhibition of corneal neovascularization. To determine if the ability of maspin to inhibit angiogenesis is involved in its antitumor activity, we used an athymic mouse xenograft ...

The Park Nicollet Institute is actively enrolling women with recurrent ovarian cancer for participation in a new clinical research study, called TRINOVA-2. Although there have been many ...

The quest for VEGF and other factors that promote tumour angiogenesis was initiated many decades ago, and a long and complicated path has led to the development of inhibitors of these molecules as ...

The process is regulated by a balance of endogenous angiogenesis stimulators (such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) and the angiopoeitin family), ...

Angiogenesis inhibitors can be divided in 2 main groups according to their mechanism of action [3]: those that act directly on microvascular endothelial cells recruited by the tumor, such as ...